Crescent Biopharma Statistics
Want to see CBIO full AI Analyst Report?
Crescent Biopharma (CBIO) Stock Statistics & Valuation Metrics
Total Valuation
Crescent Biopharma has a market cap or net worth of $550.37M. The enterprise value is $286.93M.
- Market Cap
- $550.37M
- Enterprise Value
- $286.93M
Share Statistics
Crescent Biopharma has 38,895,443 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 38,895,443
- Owned by Insiders
- 11.26%
- Owned by Institutions
- 29.33%
Financial Efficiency
Crescent Biopharma’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -74.58%.
- Return on Equity (ROE)
- -0.76
- Return on Assets (ROA)
- -0.64
- Return on Invested Capital (ROIC)
- -74.58%
- Return on Capital Employed (ROCE)
- -0.75
- Revenue Per Employee
- 246.45K
- Profits Per Employee
- -3.50M
- Employee Count
- 44
- Asset Turnover
- 0.05
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Crescent Biopharma is -2.00. Crescent Biopharma’s PEG ratio is -0.01.
- PE Ratio
- -2.00
- PS Ratio
- 36.69
- PB Ratio
- 2.01
- Price to FCF
- -3.39
- Price to Operating Cash Flow
- -6.73
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Crescent Biopharma had revenue of 10.84M and earned -153.94M in profits. Earnings per share was -14.78.
- Revenue
- 10.84M
- Gross Profit
- 10.84M
- Operating Income
- -152.63M
- Pretax Income
- -151.94M
- Net Income
- -153.94M
- EBITDA
- -149.67M
- Earnings Per Share (EPS)
- -14.78
Cash Flow
In the last 12 months, operating cash flow was -82.08M and capital expenditures -80.35M, giving a free cash flow of -162.43M billion.
- Operating Cash Flow
- -82.08M
- Free Cash Flow
- -162.43M
- Free Cash Flow per Share
- -4.16
Dividends & Yields
Crescent Biopharma pays an annual dividend of $0.24, resulting in a dividend yield of ―
- Dividend Per Share
- $0.24
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -30.90%
- Earnings Yield
- -31.86%
Stock Price Statistics
- Beta
- 1.54
- 52-Week Price Change
- 9.01%
- 50-Day Moving Average
- 14.94
- 200-Day Moving Average
- 16.07
- Relative Strength Index (RSI)
- 52.34
- Average Volume (3m)
- 348.19K
Important Dates
Crescent Biopharma upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- Jan 13, 2023
Financial Position
Crescent Biopharma as a current ratio of 6.56, with Debt / Equity ratio of 0.81%
- Current Ratio
- 6.56
- Quick Ratio
- 6.56
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.41
- Interest Coverage Ratio
- -69.85
Taxes
In the past 12 months, Crescent Biopharma has paid 2.00M in taxes.
- Income Tax
- 2.00M
- Effective Tax Rate
- -0.01
Enterprise Valuation
Crescent Biopharma EV to EBITDA ratio is -1.34, with an EV/FCF ratio of -1.47.
- EV to Sales
- 15.91
- EV to EBITDA
- -1.34
- EV to Free Cash Flow
- -1.47
- EV to Operating Cash Flow
- -2.91
Balance Sheet
Crescent Biopharma has $289.36M in cash and marketable securities with $2.46M in debt, giving a net cash position of $286.90M billion.
- Cash & Marketable Securities
- $289.36M
- Total Debt
- $2.46M
- Net Cash
- $286.90M
- Net Cash Per Share
- $7.38
- Tangible Book Value Per Share
- $7.02
Margins
Gross margin is 99.55%, with operating margin of -1216.61%, and net profit margin of -1173.97%.
- Gross Margin
- 99.55%
- Operating Margin
- -1216.61%
- Pretax Margin
- -1174.95%
- Net Profit Margin
- -1173.97%
- EBITDA Margin
- -1187.82%
- EBIT Margin
- -1189.49%
Analyst Forecast
The average price target for Crescent Biopharma is $31.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $31.00
- Price Target Upside
- 119.08% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 67.56%
Scores
- Smart Score
- 7
- AI Score
- 50

